Business Context and Reporting Period
This Form 8-K is a current report filed by Collegium Pharmaceutical, Inc. on May 6, 2021. The filing primarily addresses the announcement of financial results for the quarterly period ended March 31, 2021, and significant changes in executive leadership.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the detailed financial results for the quarter ended March 31, 2021. However, the text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes and Executive Transition
The most significant material event reported is the transition of the Chief Financial Officer (CFO):
- Resignation: Paul Brannelly resigned as Executive Vice President and CFO, effective May 24, 2021.
- Appointment: Colleen Tupper was appointed as the new Executive Vice President and CFO, effective May 24, 2021.
- Background: Ms. Tupper joins from Takeda Pharmaceuticals USA Inc., where she served as Senior Vice President & CFO of the U.S. Business Unit.
Compensation and Outlook
Ms. Tupper's compensation package includes:
- Base Salary: $435,000 annually.
- Cash Bonus: Target of 50% of the annual base salary.
- Equity Grant: 42,000 Restricted Stock Units (RSUs) and 18,000 Performance Share Units (PSUs).
- Vesting Schedule: RSUs vest 25% on February 10, 2022, with the remainder vesting in three equal annual installments. PSUs vest based on Total Stockholder Return (TSR) performance relative to the S&P Pharmaceutical Select Industry Index over a three-year period.
The filing does not contain specific forward-looking guidance, risk factors, or management commentary regarding the company's operational outlook beyond the leadership change.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2021 financial results (revenue, net loss, cash position).
- Verify the effective date of the CFO transition (May 24, 2021) and the interim financial oversight arrangements.
- Assess the impact of the new CFO's background in large-cap pharma (Takeda/Shire) on Collegium's strategic direction.
- Monitor the vesting conditions for the new CFO's equity grants, specifically the TSR performance metrics.